

AUGUST 18, 2021 ADDENDUM: Apple Health Preferred Drug List (AHPDL) Class Names

The drug classes listed in the agenda have been shortened to allow for easier organization of the topics. The classes listed below reflect the exact naming used by the Washington State Health Care Authority for the AHPDL.

| |
|---|
| ANTIPSYCHOTICS / ANTIMANIC AGENTS : ANTIPSYCHOTICS - 2ND GENERATION |
| ANTIPSYCHOTICS / ANTIMANIC AGENTS : ANTIPSYCHOTICS - COMBINATIONS |
| ANTIPSYCHOTICS / ANTIMANIC AGENTS : PARKINSONS PSYCHOTIC DISORDER |
| CYTOKINE AND CAM ANTAGONISTS : |
| MOVEMENT DISORDER AGENTS : |
| ONCOLOGY AGENTS : ANDROGEN BIOSYNTHESIS INHIBITORS - ORAL |
| ONCOLOGY AGENTS : ANTIANDROGENS - ORAL |
| ONCOLOGY AGENTS : ANTINEOPLASTICS - MISC COMBINATIONS - ORAL |
| ONCOLOGY AGENTS : BRAF KINASE INHIBITORS - ORAL |
| ONCOLOGY AGENTS : CYCLIN DEPENDENT KINASES (CDK) INHIBITORS - ORAL |
| ONCOLOGY AGENTS : FGFR KINASE INHIBITORS - ORAL |
| ONCOLOGY AGENTS : HEDGEHOG PATHWAY INHIBITORS - ORAL |
| ONCOLOGY AGENTS : MEK INHIBITORS - ORAL |
| ONCOLOGY AGENTS : MTOR KINASE INHIBITORS - ORAL |
| ONCOLOGY AGENTS : MULTIKINASE INHIBITORS - ORAL |
| ONCOLOGY AGENTS : POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS - ORAL |
| ONCOLOGY AGENTS : RETINOIDS - ORAL |
| ONCOLOGY AGENTS : TOPOISOMERASE INHIBITORS - ORAL |
| ONCOLOGY AGENTS : TROPOMYOSIN RECEPTOR KINASE INHIBITORS - ORAL |
| ONCOLOGY AGENTS : TYROSINE KINASE INHIBITORS - ORAL |
| OPHTHALMIC AGENTS : GLAUCOMA AGENTS |
| OPHTHALMIC AGENTS : IMMUNOMODULATORS |
| RESPIRATORY AGENTS : PULMONARY FIBROSING AGENTS |
| SMOKING DETERRENTS : MISC - OTHER |